Pharmacotherapy of type 2 diabetes: An update and future directions
A DeMarsilis, N Reddy, C Boutari, A Filippaios… - Metabolism, 2022 - Elsevier
Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …
social impact for which multiple conventional and novel pharmacotherapies are currently …
The role of oxidative stress in cardiac disease: from physiological response to injury factor
R D'Oria, R Schipani, A Leonardini… - Oxidative medicine …, 2020 - Wiley Online Library
Reactive oxygen species (ROS) are highly reactive chemical species containing oxygen,
controlled by both enzymatic and nonenzymatic antioxidant defense systems. In the heart …
controlled by both enzymatic and nonenzymatic antioxidant defense systems. In the heart …
SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
C Li, J Zhang, M Xue, X Li, F Han, X Liu, L Xu… - Cardiovascular …, 2019 - Springer
Background Hyperglycaemia associated with myocardial oxidative stress and fibrosis is the
main cause of diabetic cardiomyopathy. Empagliflozin, a sodium-glucose cotransporter 2 …
main cause of diabetic cardiomyopathy. Empagliflozin, a sodium-glucose cotransporter 2 …
Sodium‐glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis
Background Several trials have demonstrated protective effects from inhibition of sodium‐
glucose cotransporter 2 among patients with type 2 diabetes mellitus. There is uncertainty …
glucose cotransporter 2 among patients with type 2 diabetes mellitus. There is uncertainty …
Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced …
Background Diabetes mellitus is an important risk factor for atrial fibrillation (AF)
development. Sodium–glucose co-transporter-2 (SGLT-2) inhibitors are used for the …
development. Sodium–glucose co-transporter-2 (SGLT-2) inhibitors are used for the …
Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis
J Menne, E Dumann, H Haller, BMW Schmidt - PLoS medicine, 2019 - journals.plos.org
Background Sodium-glucose cotransporter-2 inhibitors (SGLT2is) represent a new class of
oral hypoglycemic agents used in the treatment of type 2 diabetes mellitus. They have a …
oral hypoglycemic agents used in the treatment of type 2 diabetes mellitus. They have a …
Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle‐stimulated endothelial senescence and dysfunction: protective effect of …
SH Park, E Belcastro, H Hasan, K Matsushita… - Cardiovascular …, 2021 - Springer
Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduced cardiovascular risk
in type 2 diabetes patients independently of glycemic control. Although angiotensin II (Ang II) …
in type 2 diabetes patients independently of glycemic control. Although angiotensin II (Ang II) …
The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
HC Lee, YL Shiou, SJ Jhuo, CY Chang, PL Liu… - Cardiovascular …, 2019 - Springer
Background Sodium glucose co-transporter 2 inhibitor (SGLT2i), a new class of anti-diabetic
drugs acting on inhibiting glucose resorption by kidneys, is shown beneficial in reduction of …
drugs acting on inhibiting glucose resorption by kidneys, is shown beneficial in reduction of …
Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury
S Lahnwong, S Palee, N Apaijai, S Sriwichaiin… - Cardiovascular …, 2020 - Springer
Background A sodium-glucose co-transporter 2 (SGLT-2) inhibitor had favorable impact on
the attenuation of hyperglycemia together with the severity of heart failure. However, the …
the attenuation of hyperglycemia together with the severity of heart failure. However, the …
Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats
A Aragon-Herrera, S Feijoo-Bandin… - Biochemical …, 2019 - Elsevier
Abstract The EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcome Event Trial in
patients with Type 2 Diabetes Mellitus (T2DM)) trial made evident the potentiality of …
patients with Type 2 Diabetes Mellitus (T2DM)) trial made evident the potentiality of …